Skip to main content
Top
Published in: Rheumatology International 9/2020

01-09-2020 | Arthritis | Observational Research

Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-α biologics: real-life results from a single-centre cross-sectional study

Authors: Oguz Abdullah Uyaroglu, Emrah Seyhoglu, Abdulsamet Erden, Levent Kilic, Omer Karadag, Ali Akdogan, Sule Apras Bilgen, Ali Ihsan Ertenli, Sedat Kiraz, Umut Kalyoncu

Published in: Rheumatology International | Issue 9/2020

Login to get access

Abstract

Most patients with inflammatory arthritis are at their reproductive ages. Use of anti-tumour necrosis factor alpha (anti-TNF-α) agents, one of the important treatment options for inflammatory arthritis, can cause foetal morbidity and mortality. While most studies on the effects of anti-TNF-α agents on pregnancy outcomes are about maternal exposure, the number of studies on the risks related to paternal exposure is insufficient. This study aimed to assess pregnancy periods and outcomes of the partners of male ankylosing spondylitis (AS) patients receiving anti-TNF-α treatment during the preconception period. Totally, 163 male AS patients using anti-TNF-α agents were identified from the Hacettepe University Biological Registry. Of these patients, 45 (27.6%) who declared that their partners got pregnant after initiation on anti-TNF-α agents were included. Data regarding demographics and drug exposure and pregnancy and infant outcomes were evaluated. Of 45 pregnancies, 39 (86.7%) resulted in healthy live births, 3 (6.7%) resulted in spontaneous abortion, and 3 (6.7%) were terminated with curettage. Of 39 live births, 34 (87.2%) were term and 5 (12.8%) were preterm, 30 (76.9%) had normal birth weight, 6 (15.4%) had low birth weight, and 3 (7.7%) had fetal macrosomia. No congenital malformations related to paternal exposure were observed. This study is valuable as being one of the studies providing pregnancy outcomes of partners of male AS patients receiving anti-TNF-α agents with its relatively high number of patients. The results suggested that paternal exposure to anti-TNF-α agents during preconception period could be safe on pregnancy outcomes.
Literature
2.
go back to reference Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36(3):635–641CrossRef Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB (2009) A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 36(3):635–641CrossRef
8.
go back to reference Puchner R, Danninger K, Puchner A, Pieringer H (2012) Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. Clin Exp Rheumatol 30(5):765–767PubMed Puchner R, Danninger K, Puchner A, Pieringer H (2012) Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. Clin Exp Rheumatol 30(5):765–767PubMed
Metadata
Title
Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-α biologics: real-life results from a single-centre cross-sectional study
Authors
Oguz Abdullah Uyaroglu
Emrah Seyhoglu
Abdulsamet Erden
Levent Kilic
Omer Karadag
Ali Akdogan
Sule Apras Bilgen
Ali Ihsan Ertenli
Sedat Kiraz
Umut Kalyoncu
Publication date
01-09-2020
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 9/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04518-3

Other articles of this Issue 9/2020

Rheumatology International 9/2020 Go to the issue